Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia

Dan L. Zimbroff, John M. Kane, Carol A. Tamminga, David G. Daniel, Randall J. Mack, Patricia J. Wozniak, Terri B. Sebree, Bruce A. Wallin, Kenneth B. Kashkin

Research output: Contribution to journalArticle

305 Citations (Scopus)

Abstract

Objective: This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia. Method: The patients were randomly assigned to one of the medication groups and received treatment for 8 weeks. Changes in Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, and Clinical Global Impression scores were used as evaluations of treatment efficacy. Three rating scales were used to assess extrapyramidal symptoms as well as the occurrence of adverse events and the use of medications related to extrapyramidal symptoms. Results: Both sertindole and haloperidol were comparably effective in the treatment of psychosis, and all dose levels were significantly more effective than placebo. For the treatment of negative symptoms, only sertindole, 20 mg/day, was significantly more effective than placebo. For all extrapyramidal symptom measures, sertindole was clinically and statistically indistinguishable from placebo, and rates of extrapyramidal symptoms were not dose related. All dose levels of haloperidol produced significantly more extrapyramidal symptoms than placebo or sertindole. Adverse events associated with sertindole treatment were mild in severity. Conclusions: Sertindole is a new antipsychotic agent effective for the treatment of both the positive and negative symptoms of schizophrenia, with motor side effects that are indistinguishable from those associated with placebo.

Original languageEnglish (US)
Pages (from-to)782-791
Number of pages10
JournalAmerican Journal of Psychiatry
Volume154
Issue number6
StatePublished - Jun 1997

Fingerprint

Haloperidol
Schizophrenia
Placebos
Therapeutics
Brief Psychiatric Rating Scale
Symptom Assessment
sertindole
Psychotic Disorders
Antipsychotic Agents
Safety

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Zimbroff, D. L., Kane, J. M., Tamminga, C. A., Daniel, D. G., Mack, R. J., Wozniak, P. J., ... Kashkin, K. B. (1997). Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. American Journal of Psychiatry, 154(6), 782-791.

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. / Zimbroff, Dan L.; Kane, John M.; Tamminga, Carol A.; Daniel, David G.; Mack, Randall J.; Wozniak, Patricia J.; Sebree, Terri B.; Wallin, Bruce A.; Kashkin, Kenneth B.

In: American Journal of Psychiatry, Vol. 154, No. 6, 06.1997, p. 782-791.

Research output: Contribution to journalArticle

Zimbroff, DL, Kane, JM, Tamminga, CA, Daniel, DG, Mack, RJ, Wozniak, PJ, Sebree, TB, Wallin, BA & Kashkin, KB 1997, 'Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia', American Journal of Psychiatry, vol. 154, no. 6, pp. 782-791.
Zimbroff, Dan L. ; Kane, John M. ; Tamminga, Carol A. ; Daniel, David G. ; Mack, Randall J. ; Wozniak, Patricia J. ; Sebree, Terri B. ; Wallin, Bruce A. ; Kashkin, Kenneth B. / Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. In: American Journal of Psychiatry. 1997 ; Vol. 154, No. 6. pp. 782-791.
@article{0e92b8ae68844acf89e8120dd55ab729,
title = "Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia",
abstract = "Objective: This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia. Method: The patients were randomly assigned to one of the medication groups and received treatment for 8 weeks. Changes in Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, and Clinical Global Impression scores were used as evaluations of treatment efficacy. Three rating scales were used to assess extrapyramidal symptoms as well as the occurrence of adverse events and the use of medications related to extrapyramidal symptoms. Results: Both sertindole and haloperidol were comparably effective in the treatment of psychosis, and all dose levels were significantly more effective than placebo. For the treatment of negative symptoms, only sertindole, 20 mg/day, was significantly more effective than placebo. For all extrapyramidal symptom measures, sertindole was clinically and statistically indistinguishable from placebo, and rates of extrapyramidal symptoms were not dose related. All dose levels of haloperidol produced significantly more extrapyramidal symptoms than placebo or sertindole. Adverse events associated with sertindole treatment were mild in severity. Conclusions: Sertindole is a new antipsychotic agent effective for the treatment of both the positive and negative symptoms of schizophrenia, with motor side effects that are indistinguishable from those associated with placebo.",
author = "Zimbroff, {Dan L.} and Kane, {John M.} and Tamminga, {Carol A.} and Daniel, {David G.} and Mack, {Randall J.} and Wozniak, {Patricia J.} and Sebree, {Terri B.} and Wallin, {Bruce A.} and Kashkin, {Kenneth B.}",
year = "1997",
month = "6",
language = "English (US)",
volume = "154",
pages = "782--791",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "6",

}

TY - JOUR

T1 - Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia

AU - Zimbroff, Dan L.

AU - Kane, John M.

AU - Tamminga, Carol A.

AU - Daniel, David G.

AU - Mack, Randall J.

AU - Wozniak, Patricia J.

AU - Sebree, Terri B.

AU - Wallin, Bruce A.

AU - Kashkin, Kenneth B.

PY - 1997/6

Y1 - 1997/6

N2 - Objective: This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia. Method: The patients were randomly assigned to one of the medication groups and received treatment for 8 weeks. Changes in Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, and Clinical Global Impression scores were used as evaluations of treatment efficacy. Three rating scales were used to assess extrapyramidal symptoms as well as the occurrence of adverse events and the use of medications related to extrapyramidal symptoms. Results: Both sertindole and haloperidol were comparably effective in the treatment of psychosis, and all dose levels were significantly more effective than placebo. For the treatment of negative symptoms, only sertindole, 20 mg/day, was significantly more effective than placebo. For all extrapyramidal symptom measures, sertindole was clinically and statistically indistinguishable from placebo, and rates of extrapyramidal symptoms were not dose related. All dose levels of haloperidol produced significantly more extrapyramidal symptoms than placebo or sertindole. Adverse events associated with sertindole treatment were mild in severity. Conclusions: Sertindole is a new antipsychotic agent effective for the treatment of both the positive and negative symptoms of schizophrenia, with motor side effects that are indistinguishable from those associated with placebo.

AB - Objective: This multicenter, double-blind, placebo-controlled study evaluated the efficacy and safety of three doses of sertindole (12, 20, and 24 mg/day) and haloperidol (4, 8, and 16 mg/day) in the treatment of psychotic symptoms for 497 hospitalized patients with schizophrenia. Method: The patients were randomly assigned to one of the medication groups and received treatment for 8 weeks. Changes in Positive and Negative Syndrome Scale, Scale for the Assessment of Negative Symptoms, Brief Psychiatric Rating Scale, and Clinical Global Impression scores were used as evaluations of treatment efficacy. Three rating scales were used to assess extrapyramidal symptoms as well as the occurrence of adverse events and the use of medications related to extrapyramidal symptoms. Results: Both sertindole and haloperidol were comparably effective in the treatment of psychosis, and all dose levels were significantly more effective than placebo. For the treatment of negative symptoms, only sertindole, 20 mg/day, was significantly more effective than placebo. For all extrapyramidal symptom measures, sertindole was clinically and statistically indistinguishable from placebo, and rates of extrapyramidal symptoms were not dose related. All dose levels of haloperidol produced significantly more extrapyramidal symptoms than placebo or sertindole. Adverse events associated with sertindole treatment were mild in severity. Conclusions: Sertindole is a new antipsychotic agent effective for the treatment of both the positive and negative symptoms of schizophrenia, with motor side effects that are indistinguishable from those associated with placebo.

UR - http://www.scopus.com/inward/record.url?scp=0030913838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030913838&partnerID=8YFLogxK

M3 - Article

C2 - 9167505

AN - SCOPUS:0030913838

VL - 154

SP - 782

EP - 791

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 6

ER -